

1 **Sex-specific effects of aging on the humoral immune response to repeat vaccination with the**
2 **high-dose seasonal influenza vaccine in older adults**

3
4 Janna R. Shapiro¹, Huifen Li², Rosemary Morgan¹, Yiyin Chen³, Helen Kuo¹, Xiaoxuan Ning⁴,
5 Patrick Shea⁵, Cunjin Wu⁶, Katherine Merport⁷, Rayna Saldanha⁷, Suifeng Liu⁸, Engle Abrams²,
6 Yan Chen⁹, Denise C. Kelly², Eileen Sheridan-Malone², Lan Wang¹⁰, Scott L. Zeger¹¹, Sabra L.
7 Klein^{1,5*}, and Sean X. Leng^{2,5*}
8

9 ¹ Department of International Health, Johns Hopkins Bloomberg School of Public Health,
10 Baltimore, MD, USA.

11 ² Division of Geriatric Medicine and Gerontology, Department of Medicine, Johns Hopkins
12 University School of Medicine, Baltimore, MD, USA.

13 ³ Guangdong Geriatrics Institute, Guangdong Provincial People's Hospital, Guangdong Academy
14 of Medical Sciences, Guangzhou, Guangdong, China.

15 ⁴ Department of Geriatrics, Xijing Hospital, The Fourth Military Medical University, Xi'an,
16 Shaanxi, China.

17 ⁵ W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins
18 Bloomberg School of Public Health, Baltimore, MD, USA.

19 ⁶ Department of Geriatrics, The Second Hospital of Tianjin Medical University, Tianjin, Hebei,
20 China.

21 ⁷ Zanvyl Krieger School of Arts and Science, Johns Hopkins University, Baltimore, MD, USA.

22 ⁸ Zhongshan Hospital, Xiamen University, Xiamen, Fujian, China.

23 ⁹ Department of Geriatrics, The First Affiliated Hospital of Chongqing Medical University,
24 Chongqing, Sichuan, China.

25 ¹⁰ Department of Geriatrics, The First Affiliated Hospital, Zhejiang University School of Medicine,
26 Hangzhou, Zhejiang, China

27 ¹¹ Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore,
28 MD, USA.

29 * Corresponding authors
30

31 **Running title:** Age, sex, and humoral immunity to influenza

32 **Key words:** age, sex difference, HAI antibody titer, influenza vaccination

33 **Manuscript statistics:**

34 Abstract: 172 words

35 Main text: 4,818 words

36 Figure: 5

37 Tables: 4

38 References: 70
39

40 **Contact information:** Address correspondence to Sabra Klein (sklein2@jhu.edu) or Sean Leng
41 (sleng1@jhmi.edu)
42

43 **Abstract**

44 Older adults (≥ 65 years of age) bear a significant burden of severe disease and mortality
45 associated with influenza, despite relatively high annual vaccination coverage and substantial
46 pre-existing immunity to influenza. To test the hypothesis that host factors, including age and
47 sex, play a role in determining the effect of repeat vaccination and levels of pre-existing
48 humoral immunity to influenza, we evaluated pre- and post-vaccination strain-specific
49 hemagglutination inhibition (HAI) titers in adults over 75 years of age who received a high-dose
50 influenza vaccine in at least four out of six influenza seasons (NCT02200276). Neither age, sex,
51 body mass index, frailty, nor repeat vaccination were significantly associated with post-
52 vaccination HAI titer outcomes. Pre-vaccination titers, however, were significantly predictive of
53 post-vaccination outcomes. Pre-vaccination titers to H1N1 remained constant with age, while
54 those to H3N2 and influenza B decreased substantially with age in males but not in females.
55 Our findings highlight the importance of pre-existing immunity in this highly vaccinated older
56 adult population and suggest that older males are particularly vulnerable to reduced pre-
57 existing humoral immunity to influenza from previous annual vaccination.

58 **Introduction**

59 Seasonal influenza is an important public health burden in older adults (people ≥ 65
60 years of age), particularly the oldest and frail subset¹⁻³. In the United States (U.S.), there are an
61 estimated 4 million incident cases per year in older adults, accounting for 90% of deaths
62 associated with influenza^{4,5}. The U.S. Centers for Disease Control and Prevention (CDC)
63 recommends annual influenza vaccination for prevention of influenza infection and
64 complications in people 6 months and older⁶. The high-dose inactivated influenza vaccine (HD-
65 IIV) is available to older adults and has demonstrated superior efficacy over standard-dose
66 vaccines in this vulnerable age group^{6,7}. Seasonal influenza vaccine coverage is relatively high in
67 older adults, with $>60\%$ of older Americans vaccinated annually, compared to $<40\%$ of the 18-
68 49 age group⁸.

69 Age-related immunosenescence, defined by a decline in cellular and humoral immune
70 function combined with a chronic low-grade inflammatory phenotype (CLIP)⁹⁻¹¹, is believed to
71 be the primary reason for the reduced effectiveness of influenza vaccines observed in older
72 adults¹²⁻¹⁴. Repeated annual vaccination may also have a negative effect on vaccine-induced
73 humoral immune responses as well as vaccine effectiveness (VE). For example, a recent
74 observational test-negative study using ten years of vaccination history found that in older
75 adults, VE decreased with increasing numbers of previous vaccinations but that vaccination
76 continued to offer some level of protection¹⁵. Another study over eight seasons in the general
77 adult population found that VE to H3N2, but not influenza B, was reduced among individuals
78 with frequent vaccination history compared to those without prior vaccination¹⁶. The impact of
79 repeat vaccination on H3N2 was confirmed by a meta-analysis, which found heterogeneous

80 effects of repeat vaccination overall; however, when negative effects were observed, they were
81 most pronounced for H3N2¹⁷. In contrast, a recent systematic review and meta-analysis
82 concluded that the available evidence does not support a reduction in VE with consecutive
83 repeat vaccination, but that certainty in the evidence was low¹⁸. Case control studies in both
84 Australia and Spain found beneficial effects of repeated annual vaccination on VE in older
85 adults^{19,20}, and an observational population-based study in Sweden found no differences in VE
86 between those who had been vaccinated in the current season only and those who had been
87 vaccinated in both the current and previous seasons²¹. Based on the conflicting evidence,
88 multi-season clinical studies to address the effects of aging and repeated vaccination have been
89 recommended¹⁷.

90 Mechanistically, pre-existing immunity generated to various influenza virus exposures
91 over time can have an important impact on the outcome of vaccination. According to immune
92 imprinting theory, the memory response established by an individual's first influenza exposure
93 has a lifelong effect on subsequent immune responses to infection or vaccination²². Broad pre-
94 existing immunity is thought to have negative consequences, as pre-existing antibodies can
95 suppress the response to novel influenza virus strains by reducing the amount of available
96 antigen or epitope masking^{23,24}. A theoretical benefit of HD-IIV is that pre-existing antibodies
97 cannot sequester the increased amount of antigen delivered, and, thus, more antigen is
98 available to activate memory B cells and elicit a protective response²⁵⁻²⁷. To our knowledge,
99 however, the impact of pre-existing immunity in the context of the HD-IIV has not been
100 adequately characterized.

101 In addition to age, other host factors including sex, frailty, and body mass index (BMI)
102 can impact vaccine responses in older adults. Females have been found to mount greater
103 antibody responses to HD-IIV than males²⁸. The relationship between frailty and influenza
104 vaccine responses is debated in the literature, with one study reporting frailty having a negative
105 effect²⁹, others reporting no effect³⁰⁻³⁴, and others still reporting a positive effect³⁵. Finally, in
106 older adults, obesity is significantly associated with decreased hemagglutination inhibition (HAI)
107 titers and percentage of switched memory B cells³⁶. We hypothesize that the variation across
108 studies in estimates of the effects of pre-existing immunity and repeat annual vaccination is
109 partly caused by failure to adequately account for heterogeneity and interactions among host
110 factors that likely differ across studies. To address this knowledge gap, we used a longitudinal
111 cohort of older adults over 75 years of age who had received high-dose, trivalent inactivated
112 influenza vaccine (HD-IIV3) in at least four out of six influenza seasons to estimate the impact of
113 repeat vaccination on the antibody response to HD-IIV3 and its dependence on the intersection
114 of age, sex, frailty, BMI, pre-existing immunity.

115

116 **Results**

117 **Study Participants and annual influenza immunization with HD-IIV3**

118 Over the six influenza seasons from 2014-2015 to 2019-2020, 90 individuals participated
119 in at least four study seasons and 433 doses of HD-IIV3 were. The strains included in each
120 vaccine and the study protocol are described in **Figure 1. Table 1** shows demographic and
121 clinical characteristics of the study participants. There was a slight predominance of females
122 (55.6%), and yearly study enrollment increased over time. Baseline characteristics, measured

123 during the first year of participation, were similar between males and females. The median age
124 at study enrollment was 80, and >50% of participants were classified as pre-frail as per the
125 Frailty Phenotype³⁷. Trends in the change in frailty since baseline, calculated as the difference
126 between the first and last years of participation, differed by sex. A greater proportion of males
127 improved in frailty status, whereas more females either did not change or progressed in frailty
128 status. A greater proportion of males also experienced changes in BMI over the course of the
129 study, while BMI did not change for females.

130

131 **Pre- and post-vaccination strain-specific HAI titers are high among repeatedly vaccinated**
132 **older adults**

133 Pre- and post-vaccination strain-specific HAI titer outcomes to the three HD-IIV3 vaccine
134 antigens are summarized and disaggregated by sex in **Table 2**. As expected in this highly
135 vaccinated elderly population, titers and seroprotection rates (defined as an HAI titer ≥ 40 ³⁸⁻⁴⁰)
136 were high. This was particularly true for influenza B, where 98% of the participants were
137 seroprotected prior to immunization. Post-vaccination, >94% of participants achieved
138 seroprotection for H1N1 and H3N2, while 100% of participants were seroprotected against
139 influenza B. Because of the lack of variability in post-vaccination seroprotection, this outcome
140 was omitted from further analysis. Fold-rise in titers and rates of seroconversion, as defined by
141 ≥ 4 -fold titer increase⁴¹, were relatively low but were highest for H3N2. There were no sex
142 differences in any post-vaccination outcomes. Together, these data indicate that pre-existing
143 and post-vaccination strain-specific HAI titers remained high among older adults who were
144 repeatedly vaccinated with HD-IIV3.

145

146 **Age, sex, BMI, frailty status and repeat vaccination are not associated with post-vaccination**
147 **outcomes**

148 We then assessed the relationships between pre-defined host factors (i.e., age, sex,
149 BMI, and frailty status) and post-vaccination strain-specific HAI titer outcomes. When
150 controlling for pre-vaccination titers and study year, neither age, frailty, nor BMI were
151 individually statistically-significantly associated with post-vaccine titers (**Figure 2A-C**), the fold-
152 rise in titers (**Figure 2D-F**), or the odds of seroconversion (**Figure 2G-I**) for either H1N1, H3N2 or
153 influenza B. Inclusion of interaction terms in the models allowed for analysis of sex-specific
154 contributions of age, frailty, and BMI as well as sex differences in the effects of these host
155 factors. None of the host factors had a statistically significant association with post-vaccination
156 outcomes for either males or females, and no statistically significant sex differences in post-
157 vaccination outcomes were observed.

158 The relationship between the number of years of study participation and post-
159 vaccination HAI titers outcomes was investigated to address the concern of potential negative
160 effects of repeated annual vaccination on the humoral immune response to future vaccines.
161 Vaccination status prior to study enrollment could not be verified, but leveraging the
162 longitudinal design of our study, we sought to quantify whether post-vaccination outcomes
163 declined with additional annual vaccination, and whether this effect differed by sex. There was
164 generally a negative trend between the number of years participated and post-vaccination
165 titers (**Figure 3A-D**), fold rise in titers (**Figure 3E-H**), and odds of seroconversion (**Figure 3I-L**);
166 these decreases, however, were not statistically significant.

167 Two interesting trends emerged from this analysis. First, the effect sizes were smaller
168 (i.e., closer to the null) for influenza B than for either H1N1 or H3N2, suggesting that the impact
169 of repeat vaccination may vary by influenza subtype. Secondly, there was a significant sex
170 difference in the effect of increasing years of vaccination on the odds of seroconverting to
171 H3N2 (difference in log odds = 0.38; $p = 0.023$). While there was no effect in females (OR =
172 0.988; $p = 0.959$), the odds of seroconverting to H3N2 decreased by 33% for each additional
173 year of study participation for males (OR = 0.673; $p = 0.100$) (**Figure 3K-L**). Therefore, in
174 addition to varying by virus subtype, the mechanisms through which repeated vaccination
175 affects antibody responses may be sex-specific.

176

177 **Pre-vaccination HAI titers strongly predict post-vaccination outcomes**

178 Overall, host factors and increasing years of vaccination did not significantly predict any
179 of the post-vaccination antibody titer parameters. Pre-vaccination titers, however, were strong
180 predictors of post-vaccination titers for H1N1 (slope = 0.49; 95% CI: 0.41; 0.58) (**Figure 4A**),
181 H3N2 (slope = 0.59; 95% CI: 0.52; 0.66) (**Figure 4B**), and influenza B (slope = 0.57; 95% CI: 0.50;
182 0.63) (**Figure 4C**) ($p < 0.0001$ for testing the null hypotheses that the slope is zero for each
183 antigen). Conversely, there was a strong negative association between pre-vaccination titers
184 and the fold-rise for H1N1 (slope = -0.15; 95% CI: 0.18; 0.13) (**Figure 4D**), H3N2 (slope = -0.12;
185 95% CI: -0.15; -0.10) (**Figure 4E**), and influenza B (slope = -0.13; 95% CI: -0.15; -0.11) (**Figure 4F**)
186 ($p < 0.0001$ for testing the null hypotheses that the slope to zero for all antigens), such that
187 greater pre-vaccination titers were associated with a smaller fold rise. Finally, there was a
188 similar negative association between pre-vaccination titers and the odds of seroconverting for

189 H1N1 (OR = 0.31; 95% CI: 0.21; 0.46) (**Figure 4G**), H3N2 (OR = 0.60; 95% CI: 0.50; 0.71) (**Figure**
190 **4H**), and influenza B (OR = 0.41; 95% CI: 0.31; 0.55) (**Figure 4I**) ($p < 0.0001$ for testing the null
191 hypothesis that the odds ratio is equal to one for all antigens).

192 The strength of these associations suggests that post-vaccination outcomes are
193 primarily determined by pre-existing humoral immunity. Thus, in highly vaccinated populations,
194 such as the older adult participants in this study, pre-vaccination titers are not just confounders
195 to be controlled for in the analysis of post-vaccination humoral immunity but are an outcome of
196 public health importance that illustrate durability of immunity to influenza from one season to
197 the next. Given the importance of pre-vaccination titers, we focused subsequent analyses on
198 exploring the relationships between host factors and pre-vaccination HAI titers in the context of
199 repeat annual vaccination.

200

201 **Sex modifies the relationship between age and pre-vaccination HAI titers**

202 Next, we assessed the relationships between age, frailty, BMI, and pre-vaccination titers
203 (**Figure 5A-C**). Neither frailty nor BMI were statistically significantly associated with pre-
204 vaccination HAI titers for all participants or in sex-disaggregated subgroup analysis. Further,
205 there were no statistically significant sex differences in the effects of frailty or BMI on pre-
206 vaccination HAI titers against either H1N1, H3N2, or influenza B. A statistically significant sex by
207 age interaction, however, was observed for H3N2 (**Figure 5B**) and for influenza B (**Figure 5C**), in
208 which HAI titers declined with age among male but not female participants.

209 To further interrogate the sex-specific effects of aging, expanded models controlling for
210 frailty and BMI, in addition to study year, were constructed. Coefficients from the base (i.e.,

211 controlling for study year only) and expanded models are shown in **Table 3**, and results from
212 expanded models are plotted in **Figure 5D-F**. For H1N1, HAI titers tended to increase with age
213 for both males and females, but the increase was not statistically significant (males: 0.49 units
214 per decade, $p = 0.152$; females: 0.35 units per decade, $p = 0.267$), nor was the sex difference in
215 slope ($p = 0.676$) (**Figure 5D**). For H3N2, while titers again tended to increase with age in
216 females (0.62 units per decade, $p = 0.121$), there was a decreasing trend with age in males (-
217 0.75 units per decade, $p = 0.097$), leading to a significant sex difference in age slopes (sex by age
218 interaction = 0.137; $p = 0.010$) (**Figure 5E**). For influenza B, titers again tended to increase with
219 age in females (0.33 units per decade, $p = 0.275$) but decreased by 0.78 units per decade in
220 males ($p = 0.023$) (**Figure 5F**). Like H3N2, the sex difference in the effect of age was significant
221 for influenza B ($p = 0.005$).

222 Both the base and expanded models were then amended to include cubic splines to
223 obtain more granular estimates of the effects of age on HAI titers for males and females.
224 Coefficients for both base and expanded non-linear models are shown in **Table 3**, and results
225 from expanded models are plotted in **Figure 5G-I**. The non-linear model for H1N1 did not differ
226 from the linear model, and no significant effects of age within each sex or difference between
227 the sexes were observed (**Figure 5G**). Although the trends in the linear models were similar for
228 H3N2 and influenza B, using age as a non-linear predictor revealed that different age categories
229 were driving the overall effects. For H3N2, the increase in pre-vaccination HAI titers with age in
230 females was driven by individuals in the 80-85 age category (increase of 0.67 units; $p = 0.037$),
231 and the decrease in males was driven primarily by people in the 75-80 age category (decrease
232 of 1.78 units; $p = 0.012$) (**Figure 5.H**). Thus, the sex difference was greatest at the younger end

233 of the cohort ($p = 0.036$ at 75 years of age). Conversely, increasing titers to influenza B with age
234 in females were driven by individuals in the 75-80 age category (increase of 1.2 units; $p =$
235 0.004), whereas for males there was a sharp decline in HAI titers that occurred in participants
236 90-95 years of age (decrease of 1.65 units; $p < 0.0001$) (**Figure 5.I**). Here, the sex difference in
237 pre-vaccination titers was only significant at the oldest end of the cohort ($p = 0.003$ at 95 years
238 of age). Taken together, these data illustrate sex-specific effects of aging on pre-vaccination
239 antibody titers to H3N2 and influenza B, but not H1N1.

240

241 **Controlling for sex leads to incorrect interpretations**

242 The impact of sex as a biological variable is often ignored in biomedical research^{42,43}.
243 This is particularly true in the context of aging, where attention is typically directed to
244 immunosenescence, failing to recognize that aging can have distinct effects on immune
245 function in males and females⁴⁴⁻⁴⁶. In this analysis, *a priori* hypotheses regarding sex differences
246 in the effect of age guided the inclusion of age by sex interaction terms in all models. To
247 illustrate the consequences of ignoring sex as a biological variable, however, analyses were
248 repeated controlling for sex rather than allowing age effects to vary by sex. For H3N2 and
249 influenza B, where the effect of aging was found to be statistically significantly different in
250 males as compared to females, the estimates derived by controlling for sex (black lines in **Figure**
251 **5E, F, H, I**) were not representative of either sex. In the linear models, for example, controlling
252 for sex led to the incorrect inference that titers remain constant with age, while the interaction
253 models demonstrate that this is false for both males and females.

254 In addition to conceptual reasons to interrogate sex differences, inclusion of interaction
255 terms improved the goodness-of-fit of statistical models. Goodness-of-fit of eight models for
256 each vaccine antigen were compared using Akaike’s Information Criterion (AIC) in **Table 4**,
257 where lower values indicate better relative goodness-of-fit. For antibody titers to H3N2 and
258 influenza B, despite the penalty for increasing model complexity, fit was improved by including
259 an age-sex interaction term, and the best models overall were expanded models that allowed
260 the effect of age to differ by sex. Thus, incorporating sex differences into vaccinology research
261 can lead to more robust analysis.

262
263 **Discussion**

264 In this multi-season, longitudinal study of older adults over 75 years of age, we observed
265 no statistically significant associations of age, sex, BMI, frailty, or the number of years of repeat
266 annual vaccination with any post-vaccination HAI titer outcomes. Importantly, this suggests
267 that repeat annual vaccination with HD-IIV3 does not seem to have significant positive or
268 negative effects on strain-specific HAI antibody responses in the highly vaccinated elderly
269 population but may mask the impact of other factors. Interestingly, there was some evidence to
270 suggest that particularly for H3N2, the effect of repeat vaccination does vary by sex, thus
271 supporting our hypothesis that variability in estimates of the effect of repeat vaccination in the
272 literature is caused by failure to adequately account for the contribution of host factors.

273 Pre-vaccination titers strongly predicted all post-vaccination antibody titer outcomes,
274 indicating that pre-existing humoral immunity, which may reflect the durability of humoral
275 immunity against influenza from previous seasons, is an important outcome measure to
276 consider in the highly vaccinated older adult population. Regarding age as a determinant of pre-

277 existing humoral immunity, we found that HAI titers to all three vaccine antigens stayed
278 constant in females with age but that HAI titers to H3N2 and influenza B decreased with age in
279 males, leading to significant sex differences in the effect of age for these two viruses. It has
280 previously been reported that at older ages, there is a male-bias in influenza B infection and
281 hospitalization^{47,48}. Our results thus provide a potential mechanism for this sex difference and
282 highlight the need to develop better vaccines or vaccination strategies for older males. Finally,
283 we demonstrated that failing to allow for sex-specific effects would have resulted in invalid
284 conclusions for both males and females.

285 Because older adults are disproportionately burdened by severe disease and mortality
286 from seasonal influenza, significant effort has been devoted to improving annual vaccination
287 coverage for this vulnerable population. Older adults, particularly those who are over 75 years
288 of age, can thus have decades of repeated annual influenza vaccination. Cumulatively, repeated
289 annual vaccination can lead to high pre-vaccination titers. As expected, over 72% participants
290 had a pre-vaccination HAI titer of 40 or higher to H1N1 and H3N2, and 98% participants had
291 such “seroprotection” to influenza B. High pre-existing humoral immunity has important
292 consequences in assessing humoral immune responses to influenza vaccines, as demonstrated
293 by the strong positive relationship between pre- and post-vaccination titers. Conversely, ratio-
294 based outcomes (i.e., fold rise and seroconversion) were negatively associated with pre-
295 vaccination titers, since, by definition, large denominators (pre-vaccination titers) result in
296 smaller ratios. We recently reported a similar effect in younger adult healthcare workers, where
297 mandatory vaccination policies result in exceptionally high rates of immunization⁴⁹. While some
298 argue that high levels of pre-existing antibodies interfere with the generation of *de novo*

299 immune responses^{24,27}, others suggest that ratio-based measures simply do not appropriately
300 control for imbalances in levels of pre-existing humoral immunity⁵⁰. Following the latter
301 interpretation, a “ceiling effect” is evident in our data, whereby the limit of detection of the
302 assay prohibits observing seroconversion or a large fold-rise in individuals with high levels of
303 pre-existing humoral immunity. Particularly important in older adults, where formation of *de*
304 *novo* responses is impaired by immunosenescence⁵¹, the breadth of pre-existing humoral
305 immunity and the positive predictive value for post-vaccination titers can thus be harnessed to
306 elicit protection²⁶. The clinical and scientific implications of this notion are far-reaching and
307 long-term, as the Advisory Committee on Immunization Practices (ACIP) of the CDC has
308 recommended annual influenza vaccination for anyone aged 6 months and older since 2010⁵².

309 For many vaccines, antibody titers wane over time⁵³⁻⁵⁶. Influenza vaccines are unique in
310 this respect due to the recommendation for yearly immunization and exceptional antigenic
311 diversity, which alter the dynamics of waning immunity. The constant pre-vaccination HAI titers
312 with age in females seen in our study suggest that females benefit from a booster effect from
313 each successive annual vaccination that appears to prevent antibody waning. This influenza-
314 specific effect has been reported elsewhere, where samples collected from individuals over a
315 20-year period revealed longitudinal increases in neutralizing titers to influenza⁵⁷. As an
316 explanation for their findings, the authors suggest that even as viral antigens drift over time,
317 many epitopes remain conserved. These conserved epitopes stimulate memory B cells that
318 were generated in response to previous exposures, thus periodically boosting steady-state
319 immunity⁵⁷. However, our data suggest that this effect is absent in males for H3N2 and
320 influenza B. The reasons for this sex difference are unknown, but may be attributable to the

321 compounding effects of females developing stronger responses to influenza infection and
322 vaccination throughout adulthood⁵⁸, leading to a more robust repertoire of memory B cells that
323 recognize conserved epitopes on drifted virus strains. It is speculated that in older adults,
324 consistently inferior responses among males may manifest as a lack of memory B cells that can
325 be boosted by drifted viruses to counteract waning of antibody over time, thus resulting in
326 decreasing pre-vaccination titers with age.

327 Notably the sex difference was absent for H1N1. A possible explanation for this lies in
328 the differing evolutionary rates of the three viral strains. H1N1 experiences slower evolution
329 than H3N2⁵⁹ and the influenza B/Victoria lineage⁶⁰. In addition, the global co-circulation of
330 B/Yamagata and B/Victoria lineages leads to increased exposure to divergent antigens⁶¹.
331 Accordingly, over the six influenza seasons included in our study, vaccine antigens were
332 significantly more variable for H3N2 and influenza B than for H1N1. While three H1N1 strains
333 were included in seasonal vaccines, five H3N2 strains and four influenza B strains were included
334 over the six study years. A decade-long review of the number of divergent vaccine strains that
335 our study participants may have been exposed to indicates that since 2010, the number of
336 H1N1 vaccine strains remained at a total of three, while seven H3N2 strains and five influenza B
337 were used in trivalent vaccines over this period⁶². It is thus possible that repeated exposure to
338 the same H1N1 antigen sufficiently boosted male steady-state immunity to mask sex
339 differences in the immune response. Conversely, for H3N2 and influenza B, sequential exposure
340 to drifted virus strains required robust and broad responses to allow for boosting of steady-
341 state immunity, which may have only been present in females.

342 Another possible explanation is immunological imprinting in youth, as it has a lifelong
343 impact on subsequent immune responses to influenza infection and vaccination^{22,63}. Individuals
344 in our cohort, born from 1916-1941, may have been exposed to H1N1 in their youth, while the
345 1918 pandemic virus continued to circulate, but were likely exposed to H3N2 and influenza B
346 later in life⁶⁴. Accordingly, older adults are more likely to have HAI activity against historical
347 strains of H1N1 viruses than younger subjects, but also have more restricted reactivity to
348 historical H3N2 viruses⁶⁵. Older cohorts are also relatively protected against symptomatic H1N1
349 infection compared to younger cohorts, but this pattern is reversed for H3N2^{66,67}. It is therefore
350 possible that strong immune imprinting to H1N1 virus strains masked the sex differences
351 otherwise observed for H3N2 and influenza B.

352 Our study had several strengths and limitations. First, this was an observational study
353 that was not specifically designed to interrogate sex differences in the immune response to
354 influenza vaccination. To overcome small yearly sample sizes, six influenza seasons were pooled
355 together, and statistical methods were used to control for annual variation in vaccine viruses
356 and repeated measurements on participants. The resulting multi-season nature of this work
357 improves generalizability to future influenza seasons. Secondly, the humoral immune response
358 to vaccination was solely based on strain-specific HAI titers, which are the standard in the field,
359 but lack the functional quality of microneutralization assays⁶⁸. Relying solely on serological
360 samples also prohibited more in-depth mechanistic investigation at the cellular level. Third, the
361 lack of racial diversity in our cohort must be noted, as it prohibited us from investigating race as
362 a host factor of interest, which should be considered in future studies. Although the study
363 lacked racial diversity, the cohort was diverse in terms of age at vaccination, allowing us to

364 study effects in the ‘oldest’ old subset. Finally, a major strength of this study is the
365 intersectional approach to this analysis, which allowed for interrogation of effects both
366 between and within groups (i.e., between and among males and females), leading to a richer
367 and more nuanced interpretation⁶⁹.

368 In conclusion, we demonstrated that in highly vaccinated older adults, pre-vaccination
369 HAI titers, rather than age, sex, BMI, frailty, or repeat vaccination, predict post-vaccination
370 parameters of humoral immunity. Further, these pre-vaccination titers change with age in a
371 sex-specific manner such that older males are particularly vulnerable to lower levels of pre-
372 existing humoral immunity. Further research should focus on elucidating the mechanisms
373 underlying this sex difference, as well as novel vaccination strategies to harness the breadth of
374 pre-existing immunity in older adults and better protect this vulnerable population.

375

376 **Methods**

377 **Study population and protocol**

378 During the 2014-2015 to 2019-2020 influenza seasons, we enrolled community-dwelling
379 older adults above 75 years of age who had not yet received a seasonal influenza vaccine.
380 Individuals who had a history of allergic reaction to influenza vaccines or to eggs, were
381 currently taking oral steroids or had worsening or new-onset of immune-modulating conditions
382 were excluded. Study participants came to the Clinical Research Unit at Johns Hopkins Institute
383 of Clinical and Translational Research on the Johns Hopkins Bayview Medical Center campus, or
384 study visits were done at participants’ home as needed. A detailed medical history was
385 obtained, vital signs were measured and frailty was assessed as per the Frailty Phenotype³⁷.

386 After a pre-vaccination blood draw, participants received HD-IIV3 (Fluzone® High-Dose Sanofi
387 Pasteur, PA, USA). A second blood sample was collected 21 to 28 days after vaccine
388 administration (**Figure 1**). To focus on the context of repeat annual vaccination, only individuals
389 who participated for a minimum of 4 study years were included in this analysis.

390

391 **Ethics**

392 Written, informed consent was obtained from all participants. The study protocol was
393 approved by the Johns Hopkins School of Medicine Institutional Review Board. The study is
394 registered on clinicaltrials.gov (NCT02200276).

395

396 **Hemagglutination inhibition assays**

397 A validated HAI assay was used to quantify antibody titers against study vaccine
398 antigens for the three vaccine strains (H1N1, H3N2 and B) in each year and were performed by
399 Sanofi Pasteur as previously described⁷⁰. Briefly, serum was incubated with type III
400 neuraminidase to eliminate non-specific inhibitors and then with turkey red blood cells to
401 adsorb non-specific agglutinins. Sera were then serially diluted in duplicate, beginning at a 1:10
402 dilution, and incubated with influenza virus (4 hemagglutination units/25µl). Turkey red blood
403 cells were then added, and the titer defined as the highest dilution in which hemagglutination
404 was inhibited.

405

406 **Definitions and categorization of predictor variables**

407 Sex was used as a dichotomous variable based on self-report. Age was calculated based
408 on the date of vaccination and used as a continuous variable. The frailty assessment was based
409 on the presence or absence of five measurable characteristics: slowed motor performance (by
410 walking speed), poor endurance and energy (by self-report of exhaustion), weakness (by grip
411 strength), shrinking (by unintentional weight loss), and low physical activity (self-report)^{29,37}.
412 Participants with three or more out of these five characteristics were defined as frail, those
413 with one or two as prefrail, and those with none as non-frail. BMI was calculated based on
414 measured height and weight and used as a continuous variable. Study year refers to the
415 influenza season (i.e., 2014-2015 to 2019-2020) and was used as categorical variable so as not
416 to imply a linear relationship from year-to-year. Number of years of study participation was
417 defined as the number of vaccines administered to an individual as part of the study and was
418 used as a continuous variable ranging from 1 to 6.

419

420 **Outcome variables**

421 Geometric mean titers were calculated both pre- and post-vaccination. For regression
422 analysis, titers were transformed to a \log_2 scale to achieve an approximately normal
423 distribution. The fold-rise in titer was calculated as post-vaccination titers divided by pre-
424 vaccination titers, and \log_{10} transformed to achieve a normal distribution. Seroconversion was
425 defined as achieving a fold-rise ≥ 4 and used as a binary outcome. Seroprotection was defined as
426 a titer $\geq 1:40$ and used as a binary outcome.

427

428

429 **Statistical analysis**

430 To account for repeated measures on participants, multi-level mixed effects models
431 with random intercepts on the individual were used. Following standard risk factor analysis
432 procedure, the contributions of host factors of interest were first assessed individually. Based
433 on the *a priori* hypotheses of this analysis, fixed effects of the base models for post-vaccination
434 outcomes adjusted for study year, pre-vaccination titers and included interaction terms to
435 allow the effect of the host factor to differ for males and females. Fixed effects of the base
436 models for pre-vaccination titers adjusted for study year and included interaction terms to
437 allow effects to differ by sex. Where significant sex differences were found, further analysis
438 controlled for additional covariates, and used cubic B-splines to investigate non-linear
439 relationships⁷¹. The relative goodness-of-fit of various models were compared using Akaike's
440 Information Criterion. For graphs, predictions were capped at 95 years of age due to low
441 sample size and large uncertainty in estimates above 95 years. Coefficients were considered
442 statistically significant if 95% confidence intervals did not span the null value of zero (i.e.,
443 $p < 0.05$). Analysis was performed in Stata 15 (StataCorp).

444

445 **Data Availability**

446 The data that support the findings of this study are available from the corresponding
447 author upon request.

448

449 **Acknowledgements**

450 The authors thank the participants, as well as the clinical staff at the Healthy Aging
451 Studies Unit and the Johns Hopkins University Institute for Clinical and Translational Research.
452 The authors would also like to than Dr. Andrew Pekosz for helpful discussion and feedback.
453 Sanofi Pasteur provided HD-IIV3 and performed HAI testing, but remained blinded to the results
454 and had no further scientific input. This work was supported in part by National Institute of
455 Health (NIH)/National Institute of Allergy and Infectious Diseases R01 AI108907 to S.X.L.,
456 NIH/National Institute on Aging Specialized Center of Research Excellence U54 AG062333
457 awarded to S.L.K., and funding from Irma and Paul Milstein Program for Senior Health, Milstein
458 Medical Asian American Partnership (MMAAP) Foundation of USA to S.X.L. J.R.S was supported
459 by a training award from the Fonds de recherche du Québec – Santé (File #287609). C.J.W,
460 X.X.N, and S.F.L. were supported by Irma and Paul Milstein Program for Senior Health
461 fellowship awards from MMAAP Foundation of USA (www.mmaapf.org).

462

463 **Author contributions**

464 S.X.L. designed and oversaw the study. E.A., D.C.K. and E.S-M collected data and biological
465 samples. H.F.L., Y.Y.C., Y.C., C.J.W., X.X.N., L.W., and S.F.L. processed biological samples. J.R.S.,
466 K.M., and R.S. entered and cleaned data. J.R.S. conceived of analytical approach and
467 experimental questions and performed analyses under mentorship of S.L.Z, R.M., and S.L.K.
468 K.M., H.K., and P.S. contributed to analyses. J.R.S. wrote the manuscript, with significant
469 editorial contributions and discussion from S.L.K., R.M., S.L.Z., and S.X.L. All authors reviewed,

470 edited, and approved the final draft of the manuscript. All authors are accountable for the
471 accuracy and integrity of the work.

472

473 **Competing Interests Statement**

474 The authors have no competing interests to declare.

475

476 **References**

- 477 1 Macias, A. E. *et al.* The disease burden of influenza beyond respiratory illness. *Vaccine*
478 (2020).
- 479 2 Iuliano, A. D. *et al.* Estimates of global seasonal influenza-associated respiratory
480 mortality: a modelling study. *Lancet* **391**, 1285-1300 (2018).
- 481 3 Global Burden of Disease Influenza Collaborators *et al.* Mortality, morbidity, and
482 hospitalisations due to influenza lower respiratory tract infections, 2017: an analysis for
483 the Global Burden of Disease Study 2017. *Lancet Respir Medicine* **7**, 69-89,
484 doi:10.1016/s2213-2600(18)30496-x PMID - 30553848 (2018).
- 485 4 Gnanasekaran, G., Biedenbender, R., Davidson, H. E. & Gravenstein, S. Vaccinations for
486 the Older Adult. *Clin Geriatr Med* **32**, 609-625, doi:10.1016/j.cger.2016.03.001 PMID -
487 27394026 (2016).
- 488 5 Hamborsky, J., Kroger, A. & Wolfe, S. *Epidemiology and prevention of vaccine-*
489 *preventable diseases.* (US Department of Health & Human Services, Centers for Disease
490 Control and Prevention 2015).
- 491 6 Grohskopf, L. A. *et al.* Prevention and control of seasonal influenza with vaccines:
492 recommendations of the Advisory Committee on Immunization Practices—United
493 States, 2020–21 influenza season. *MMWR Recommendations and Reports* **69**, 1 (2020).
- 494 7 DiazGranados, C. A. *et al.* Efficacy of High-Dose versus Standard-Dose Influenza Vaccine
495 in Older Adults. *New England Journal of Medicine* **371**, 635-645,
496 doi:10.1056/nejmoa1315727 PMID - 25119609 (2014).
- 497 8 Centers for Disease Control and Prevention. (2020).
- 498 9 Crooke, S. N., Ovsyannikova, I. G., Poland, G. A. & Kennedy, R. B. Immunosenescence: A
499 systems-level overview of immune cell biology and strategies for improving vaccine
500 responses. *Exp Gerontol* **124**, 110632, doi:10.1016/j.exger.2019.110632 PMID -
501 31201918 (2019).
- 502 10 Weinberger, B. Vaccines for the elderly: current use and future challenges. *Immunity &*
503 *ageing : I & A* **15**, 3, doi:10.1186/s12979-017-0107-2 PMID - 29387135 (2018).
- 504 11 Chen, Y., Liu, S. & Leng, S. X. Chronic low-grade inflammatory phenotype (CLIP) and
505 senescent immune dysregulation. *Clinical therapeutics* **41**, 400-409 (2019).
- 506 12 Demicheli, V., Jefferson, T., Ferroni, E., Rivetti, A. & Di Pietrantonj, C. Vaccines for
507 preventing influenza in healthy adults. *Cochrane database of systematic reviews* (2018).

- 508 13 Nichols, M. K. *et al.* Influenza vaccine effectiveness to prevent influenza-related
509 hospitalizations and serious outcomes in Canadian adults over the 2011/12 through
510 2013/14 influenza seasons: A pooled analysis from the Canadian Immunization Research
511 Network (CIRN) Serious Outcomes Surveillance (SOS Network). *Vaccine* **36**, 2166-2175,
512 doi:10.1016/j.vaccine.2018.02.093 PMID - 29548608 (2018).
- 513 14 Rondy, M. *et al.* Effectiveness of influenza vaccines in preventing severe influenza illness
514 among adults: a systematic review and meta-analysis of test-negative design case-
515 control studies. *Journal of Infection* **75**, 381-394 (2017).
- 516 15 Kwong, J. C. *et al.* The impact of repeated vaccination using 10-year vaccination history
517 on protection against influenza in older adults: a test-negative design study across the
518 2010/11 to 2015/16 influenza seasons in Ontario, Canada. *Eurosurveillance* **25**, 1900245
519 (2020).
- 520 16 McLean, H. Q. *et al.* Impact of Repeated Vaccination on Vaccine Effectiveness Against
521 Influenza A(H3N2) and B During 8 Seasons. *Clin Infect Dis* **59**, 1375-1385,
522 doi:10.1093/cid/ciu680 PMID - 25270645 (2014).
- 523 17 Belongia, E. A. *et al.* Repeated annual influenza vaccination and vaccine effectiveness:
524 review of evidence. *Expert Review of Vaccines* **16**, 723-736,
525 doi:10.1080/14760584.2017.1334554 PMID - 28562111 (2017).
- 526 18 Bartoszko, J. J. *et al.* Does consecutive influenza vaccination reduce protection against
527 influenza: A systematic review and meta-analysis. *Vaccine* **36**, 3434-3444,
528 doi:10.1016/j.vaccine.2018.04.049 PMID - 29724509 (2018).
- 529 19 Cheng, A. C. *et al.* Repeated Vaccination Does Not Appear to Impact Upon Influenza
530 Vaccine Effectiveness Against Hospitalization With Confirmed Influenza. *Clin Infect Dis*
531 **64**, 1564-1572, doi:10.1093/cid/cix209 PMID - 28329167 (2017).
- 532 20 Casado, I. *et al.* Repeated influenza vaccination for preventing severe and fatal influenza
533 infection in older adults: a multicentre case-control study. *Canadian Medical*
534 *Association Journal* **190**, E3-E12, doi:10.1503/cmaj.170910 PMID - 29311098 (2018).
- 535 21 Örtqvist, Å., Brytting, M., Leval, A. & Hergens, M.-P. Impact of repeated influenza
536 vaccinations in persons over 65 years of age: A large population-based cohort study of
537 severe influenza over six consecutive seasons, 2011/12–2016/17. *Vaccine* **36**, 5556-
538 5564, doi:10.1016/j.vaccine.2018.07.052 PMID - 30076104 (2018).
- 539 22 Jang, H. & Ross, T. M. Preexisting influenza specific immunity and vaccine effectiveness.
540 *Expert Review of Vaccines* **18**, 1-9, doi:10.1080/14760584.2019.1675519 PMID -
541 31575308 (2019).
- 542 23 Henry, C., Palm, A.-K. E., Krammer, F. & Wilson, P. C. From Original Antigenic Sin to the
543 Universal Influenza Virus Vaccine. *Trends Immunol* **39**, 70-79,
544 doi:10.1016/j.it.2017.08.003 PMID - 28867526 (2018).
- 545 24 Linderman, S. L. *et al.* Influenza Immunization in the Context of Preexisting Immunity.
546 *Csh Perspect Med*, a040964, doi:10.1101/cshperspect.a040964 PMID - 32988981 (2020).
- 547 25 Guthmiller, J. J., Utset, H. A. & Wilson, P. C. B Cell Responses against Influenza Viruses:
548 Short-Lived Humoral Immunity against a Life-Long Threat. *Viruses* **13**, 965 (2021).
- 549 26 Guthmiller, J. J. & Wilson, P. C. Harnessing immune history to combat influenza viruses.
550 *Current Opinion in Immunology* **53**, 187-195, doi:10.1016/j.coi.2018.05.010 PMID -
551 29890370 (2018).

- 552 27 Ellebedy, A. H. Immunizing the Immune: Can We Overcome Influenza's Most Formidable
553 Challenge? *Nato Adv Sci Inst Se* **6**, 68, doi:10.3390/vaccines6040068 PMID - 30248996
554 (2018).
- 555 28 Falsey, Ann R., Treanor, John J., Tornieporth, N., Capellan, J. & Gorse, Geoffrey J.
556 Randomized, Double-Blind Controlled Phase 3 Trial Comparing the Immunogenicity of
557 High-Dose and Standard-Dose Influenza Vaccine in Adults 65 Years of Age and Older. *J*
558 *Infect Dis* **200**, 172-180, doi:10.1086/599790 PMID - 19508159 (2009).
- 559 29 Yao, X. *et al.* Frailty is associated with impairment of vaccine-induced antibody response
560 and increase in post-vaccination influenza infection in community-dwelling older adults.
561 *Vaccine* **29**, 5015-5021, doi:10.1016/j.vaccine.2011.04.077 PMID - 21565245 (2011).
- 562 30 Narang, V. *et al.* Influenza Vaccine-Induced Antibody Responses Are Not Impaired by
563 Frailty in the Community-Dwelling Elderly With Natural Influenza Exposure. *Front*
564 *Immunol* **9**, 2465, doi:10.3389/fimmu.2018.02465 PMID - 30405641 (2018).
- 565 31 Epps, P. V. *et al.* Preexisting Immunity, Not Frailty Phenotype, Predicts Influenza
566 Postvaccination Titers among Older Veterans. *Clin Vaccine Immunol* **24**, e00498-00416,
567 doi:10.1128/cvi.00498-16 PMID - 28100496 (2017).
- 568 32 Bauer, J. M. *et al.* Influenza vaccine response in community-dwelling German prefrail
569 and frail individuals. *Immun Ageing* **14**, 17, doi:10.1186/s12979-017-0098-z PMID -
570 28694834 (2017).
- 571 33 Moehling, K. K. *et al.* The effect of frailty on HAI response to influenza vaccine among
572 community-dwelling adults ≥ 50 years of age. *Hum Vacc Immunother* **14**, 361-367,
573 doi:10.1080/21645515.2017.1405883 PMID - 29172948 (2017).
- 574 34 Moehling, K. K. *et al.* The impact of physical frailty on the response to inactivated
575 influenza vaccine in older adults. *Aging* **12**, doi:10.18632/aging.202207 PMID -
576 33347425 (2020).
- 577 35 Loeb, N. *et al.* Frailty is associated with increased hemagglutination-inhibition titres in a
578 4-year randomized trial comparing standard and high dose influenza vaccination. *Open*
579 *Forum Infect Dis* **7**, ofaa148, doi:10.1093/ofid/ofaa148 PMID - 32500087 (2020).
- 580 36 Frasca, D. *et al.* Obesity decreases B cell responses in young and elderly individuals.
581 *Obesity* **24**, 615-625, doi:10.1002/oby.21383 PMID - 26857091 (2016).
- 582 37 Fried, L. P. *et al.* Frailty in Older Adults: Evidence for a Phenotype. *Journals Gerontology*
583 *Ser Biological Sci Medical Sci* **56**, M146-M157, doi:10.1093/gerona/56.3.m146 PMID -
584 11253156 (2001).
- 585 38 Ward, B. J. *et al.* The establishment of surrogates and correlates of protection: Useful
586 tools for the licensure of effective influenza vaccines? *Hum Vacc Immunother* **14**, 647-
587 656, doi:10.1080/21645515.2017.1413518 PMID - 29252098 (2018).
- 588 39 Al-Khayatt, R., Jennings, R. & Potter, C. Interpretation of responses and protective levels
589 of antibody against attenuated influenza A viruses using single radial haemolysis.
590 *Epidemiology & Infection* **93**, 301-312 (1984).
- 591 40 Hobson, D., Curry, R., Beare, A. & Ward-Gardner, A. The role of serum
592 haemagglutination-inhibiting antibody in protection against challenge infection with
593 influenza A2 and B viruses. *Epidemiology & Infection* **70**, 767-777 (1972).

- 594 41 Reber, A. & Katz, J. Immunological assessment of influenza vaccines and immune
595 correlates of protection. *Expert Review of Vaccines* **12**, 519-536, doi:10.1586/erv.13.35
596 PMID - 23659300 (2013).
- 597 42 Shapiro, J. R., Klein, S. L. & Morgan, R. Stop 'controlling' for sex and gender in global
598 health research. *Bmj Global Heal* **6**, e005714, doi:10.1136/bmjgh-2021-005714 (2021).
- 599 43 Klein, S. L., Jedlicka, A. & Pekosz, A. The Xs and Y of immune responses to viral vaccines.
600 *Lancet Infect Dis* **10**, 338-349, doi:10.1016/s1473-3099(10)70049-9 PMID - 20417416
601 (2010).
- 602 44 Klein, S. L. & Gearhart, P. J. Commentary for the 'VSI: Aging and sex in immunity'. *Cell*
603 *Immunol* **348**, 104037, doi:10.1016/j.cellimm.2019.104037 PMID - 31992440 (2020).
- 604 45 Potluri, T. *et al.* Age-associated changes in the impact of sex steroids on influenza
605 vaccine responses in males and females. *Npj Vaccines* **4**, 29, doi:10.1038/s41541-019-
606 0124-6 PMID - 31312529 (2019).
- 607 46 Bupp, M. R. G., Potluri, T., Fink, A. L. & Klein, S. L. The Confluence of Sex Hormones and
608 Aging on Immunity. *Front Immunol* **9**, 1269, doi:10.3389/fimmu.2018.01269 PMID -
609 29915601 (2018).
- 610 47 Wong, K. C., Luscombe, G. M. & Hawke, C. Influenza infections in Australia 2009–2015: is
611 there a combined effect of age and sex on susceptibility to virus subtypes? *BMC*
612 *Infectious Diseases* **19**, 42, doi:10.1186/s12879-019-3681-4 PMID - 30630435 (2019).
- 613 48 Wang, X.-L. *et al.* Age and Sex Differences in Rates of Influenza-Associated
614 Hospitalizations in Hong Kong. *Am J Epidemiol* **182**, 335-344, doi:10.1093/aje/kwv068
615 PMID - 26219977 (2015).
- 616 49 Kuo, H. *et al.* Sex-specific effects of age and body mass index on antibody responses to
617 seasonal influenza vaccines in healthcare workers. *Vaccine* (2021).
- 618 50 Nauta, J. Statistics in Clinical Vaccine Trials - Adjusting for Imbalance in Pre-Vaccination
619 State. 57-65, doi:10.1007/978-3-642-14691-6_5 (2010).
- 620 51 Weinberger, B., Herndler-Brandstetter, D., Schwanninger, A., Weiskopf, D. & Grubeck-
621 Loebenstein, B. Biology of Immune Responses to Vaccines in Elderly Persons. *Clin Infect*
622 *Dis* **46**, 1078-1084, doi:10.1086/529197 PMID - 18444828 (2008).
- 623 52 Centers for Disease Control and Prevention. *Influenza Historic Timeline*,
624 <[https://www.cdc.gov/flu/pandemic-resources/pandemic-timeline-1930-and-](https://www.cdc.gov/flu/pandemic-resources/pandemic-timeline-1930-and-beyond.htm)
625 [beyond.htm](https://www.cdc.gov/flu/pandemic-resources/pandemic-timeline-1930-and-beyond.htm)> (2019).
- 626 53 Bitzegeio, J., Majowicz, S., Matysiak-Klose, D., Sagebiel, D. & Werber, D. Estimating age-
627 specific vaccine effectiveness using data from a large measles outbreak in Berlin,
628 Germany, 2014/15: evidence for waning immunity. *Eurosurveillance* **24**, 1800529 (2019).
- 629 54 Crooke, S. N. *et al.* Durability of humoral immune responses to rubella following MMR
630 vaccination. *Vaccine* **38**, 8185-8193 (2020).
- 631 55 Savage, R. D. *et al.* A multisite study of pertussis vaccine effectiveness by time since last
632 vaccine dose from three Canadian provinces: A Canadian Immunization Research
633 Network study. *Vaccine* **39**, 2772-2779 (2021).
- 634 56 Posuwan, N. *et al.* The success of a universal hepatitis B immunization program as part
635 of Thailand's EPI after 22 years' implementation. *Plos One* **11**, e0150499 (2016).
- 636 57 Miller, M. S. *et al.* Neutralizing Antibodies Against Previously Encountered Influenza
637 Virus Strains Increase over Time: A Longitudinal Analysis.

- 638 58 Flanagan, K. L., Fink, A. L., Plebanski, M. & Klein, S. L. Sex and Gender Differences in the
639 Outcomes of Vaccination over the Life Course. *Annu Rev Cell Dev Bi* **33**, 577-599,
640 doi:10.1146/annurev-cellbio-100616-060718 PMID - 28992436 (2017).
- 641 59 Liu, M. *et al.* Antigenic patterns and evolution of the human influenza A (H1N1) virus.
642 *Scientific reports* **5**, 1-8 (2015).
- 643 60 Vijaykrishna, D. *et al.* The contrasting phylodynamics of human influenza B viruses. *Elife*
644 **4**, e05055 (2015).
- 645 61 Caini, S. *et al.* The epidemiological signature of influenza B virus and its B/Victoria and
646 B/Yamagata lineages in the 21st century. *Plos One* **14**, e0222381,
647 doi:10.1371/journal.pone.0222381 PMID - 31513690 (2019).
- 648 62 World Health Organization. *WHO recommendations on the composition of influenza*
649 *virus vaccines*, <<https://www.who.int/influenza/vaccines/virus/recommendations/en/>>
650 (2021).
- 651 63 Auladell, M. *et al.* Recalling the Future: Immunological Memory Toward Unpredictable
652 Influenza Viruses. *Front Immunol* **10**, 1400, doi:10.3389/fimmu.2019.01400 PMID -
653 31312199 (2019).
- 654 64 Hannoun, C. The evolving history of influenza viruses and influenza vaccines. *Expert*
655 *review of vaccines* **12**, 1085-1094 (2013).
- 656 65 Nuñez, I. A. *et al.* Impact of age and pre-existing influenza immune responses in humans
657 receiving split inactivated influenza vaccine on the induction of the breadth of
658 antibodies to influenza A strains. *Plos One* **12**, e0185666,
659 doi:10.1371/journal.pone.0185666 PMID - 29091724 (2017).
- 660 66 Khiabani, H., Farrell, G. M., George, K. S. & Rabadan, R. Differences in patient age
661 distribution between influenza A subtypes. *Plos One* **4**, e6832 (2009).
- 662 67 Gostic, K. M. *et al.* Childhood immune imprinting to influenza A shapes birth year-
663 specific risk during seasonal H1N1 and H3N2 epidemics. *PLOS Pathogens* **15**, e1008109,
664 doi:10.1371/journal.ppat.1008109 PMID - 31856206 (2019).
- 665 68 Dunning, A. J. *et al.* Correlates of Protection against Influenza in the Elderly: Results
666 from an Influenza Vaccine Efficacy Trial. *Clin Vaccine Immunol* **23**, 228-235,
667 doi:10.1128/cvi.00604-15 PMID - 26762363 (2016).
- 668 69 Shapiro, J. R., Klein, S. L. & Morgan, R. COVID-19: use intersectional analyses to close
669 gaps in outcomes and vaccination. *Nature* **591**, 202 (2021).
- 670 70 Greenberg, D. P. *et al.* Safety and immunogenicity of a quadrivalent inactivated
671 influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults.
672 *Vaccine* **31**, 770-776 (2013).
- 673 71 Newson, R. B. Sensible parameters for univariate and multivariate splines. *The Stata*
674 *Journal* **12**, 479-504 (2012).
- 675

676 **Figure Legends**

677 **Figure 1. Study design**

678 Study procedures and the three strains included in each seasonal HD-IIV3 are shown. Serum
679 from blood draws was used to evaluate pre- and post-vaccination strain-specific
680 hemagglutination antibody inhibition (HAI) titers, and frailty was assessed using the Frailty
681 Phenotype.

682

683 **Figure 2. Relationship of age, frailty status, and BMI with post-vaccination hemagglutination
684 antibody inhibition (HAI) titers outcomes**

685 The relationship of age (in decades, Age/10), frailty status, and BMI (five-unit intervals, BMI/5)
686 with log₂-transformed post-vaccination titers are shown as slopes for HAI titers against H1N1
687 (a), H3N2 (b) and influenza B (c). The relationships of these host factors with log₁₀-transformed
688 fold-rise in titers (post-titer/pre-titer) are shown as slopes for H1N1 (d), H3N2 (e) and influenza
689 B (f). Their relationships with log odds of seroconversion are shown for H1N1 (g), H3N2 (h) and
690 influenza B (i). Estimates and 95% confidence intervals were derived from multi-level mixed
691 effects models with random intercepts on the individual participant. Models controlled for
692 study year and pre-vaccination HAI titers, and either controlled for sex (whole population
693 estimates) or used interaction terms between sex and the host factor of interest to derive sex-
694 specific estimates.

695

696 **Figure 3. Relationship of repeat annual vaccination with post-vaccination hemagglutination
697 antibody inhibition (HAI) titer outcomes**

698 The relationship between increasing years of vaccination and \log_2 -transformed post-vaccination
699 HAI titers are shown for each vaccine antigen (**a-c**), with slopes summarized (**d**). Similarly, the
700 relationship between increasing years of vaccination and the \log_{10} -transformed fold-rise in
701 titers are shown for H1N1, H3N2, and influenza B (**e-g**), with the slopes summarized (**h**). The
702 relationship between increasing years of vaccination and probability of seroconversion are
703 shown for antibody responses against H1N1, H3N2, and influenza B, respectively (**i-k**), with the
704 logs odds ratios summarized (**l**). All models controlled for study year, pre-vaccination titers, and
705 age at vaccination. Whole-population models controlled for sex, while sex-specific estimates
706 were derived from models including an interaction term between sex and years of participation
707 and are shown with 95% confidence intervals. Asterisks indicate significant sex differences.

708

709 **Figure 4. Relationship between pre-vaccination hemagglutination antibody inhibition (HAI)**
710 **titers and post-vaccination HAI titer outcomes**

711 Relationships between \log_2 -transformed pre-vaccination HAI titers and \log_2 -transformed post-
712 vaccination titers are shown for responses to H1N1, H3N2, and influenza B, respectively (**a-c**),
713 with slopes summarized (**d**). The relationships between pre-vaccination HAI titers and the \log_{10} -
714 transformed fold-rise in titers are shown for each vaccine antigen (**e-g**), with the slopes
715 summarized (**h**). The relationships between pre-vaccination HAI titers and the probability of
716 seroconversion are shown for H1N1, H3N2, and influenza B, respectively (**i-k**), with the log odds
717 ratios summarized (**l**). All models controlled for study year. Overall estimates controlled for sex,
718 while sex-specific estimates were derived from models that included an interaction term
719 between sex and pre-vaccination titers and are shown with 95% confidence intervals.

720

721 **Figure 5. Relationship of age, frailty status, and BMI to pre-vaccination hemagglutination**
722 **antibody inhibition (HAI) titers**

723 Estimates for the relationship of age in decades (Age/10), frailty status, and BMI (five-unit

724 intervals, BMI/5) to pre-vaccination HAI titers were derived from multilevel mixed-effects

725 models controlling for study year for H1N1 (a), H3N2 (b), and influenza B (c). Expanded age

726 models controlling for frailty and BMI are shown for responses to H1N1 (d), H3N2 (e), and

727 influenza B (f). Expanded models for responses to H1N1 (g), H3N2 (h), and influenza B (i) were

728 then amended to include cubic B-splines for age with knots at 5-year intervals. Models for the

729 whole study population adjusted for sex, while sex-specific estimates included an interaction

730 term allowing effects to differ by sex and are shown with 95% confidence intervals. Asterisks

731 indicate significant sex differences.

732

733 **Tables**

734 **Table 1. Summary of study population characteristics**

	All	Male	Female
Person-seasons - n (%)	433	192 (44.3)	241 (55.7)
Individuals - n (%)	90	40 (44.4)	50 (55.6)
Yearly participation - n (%)			
2014	45 (50.0)	19 (47.5)	26 (52.0)
2015	68 (75.6)	28 (70.0)	40 (80.0)
2016	68 (75.6)	31 (77.5)	37 (74.0)
2017	87 (96.7)	38 (95.0)	49 (98.0)
2018	88 (97.8)	40 (100.0)	48 (96.0)
2019	77 (85.6)	36 (90.0)	41 (82.0)
Number of years participated			
4	40 (44.4)	18 (45.0)	22 (44.0)
5	27 (30.0)	12 (30.0)	15 (30.0)
6	23 (25.6)	10 (25.0)	13 (26.0)
Birth year - Median (p25-p75)	1934 (1930 - 1938)	1934 (1929 - 1938)	1934 (1930 - 1938)
Range	1916 - 1941	1922 - 1941	1916 - 1940
Baseline characteristics^a			
Age - Median (p25-p75)	80 (77 - 83)	80 (77 - 84)	80 (77 - 83)
Frailty - n (%)			
Non-frail	37 (41.1)	17 (42.5)	20 (40.0)
Pre-frail	48 (53.3)	21 (52.5)	27 (54.0)
Frail	5 (5.6)	2 (5.0)	3 (6.0)
BMI - Median (p25-p75)	26.8 (24.5 - 30.4)	27.0 (25.3 - 29.6)	26.5 (23.2 - 30.5)
Change from baseline^b			
Frailty - n (%)			
Improved	11 (12.2)	8 (20.0)	3 (6.0)
No change	44 (48.9)	18 (45.0)	26 (52.0)
Worsened	35 (38.9)	14 (35.0)	21 (42.0)
BMI			
Decreased	39 (43.3)	19 (47.5)	20 (40.0)
No change (+/- 1)	38 (42.2)	14 (35.0)	24 (48.0)
Increased	13 (14.4)	7 (17.5)	6 (12.0)

^a Value for first year participated

^b Difference between first and last year participated

736 **Table 2. Pre- and post-vaccination hemagglutination antibody inhibition (HAI) titer outcomes**

	All	Males	Females	Sex difference*
Person-seasons - n (%)	433	192 (44.3)	241 (55.7)	
H1N1				
Pre-vaccination - GMT (95% CI)	74.3 (66.8 - 82.8)	81.7 (70.7 - 94.4)	69.0 (59.0 - 80.6)	0.4451
Post-vaccination - GMT (95% CI)	192.3 (174.6 - 211.9)	185.9 (161.5 - 213.9)	197.7 (173.0 - 225.9)	0.8922
Pre-vaccination SPR - n (%)	325 (75.1)	149 (77.6)	176 (73.0)	0.4116
Post-vaccination SPR - n (%)	415 (95.8)	184 (95.8)	231 (95.9)	0.7837
Fold-rise (log10) - mean (95% CI)	0.413 (0.376 - 0.450)	0.357 (0.308 - 0.406)	0.457 (0.405 - 0.510)	0.1711
Seroconversion rate - n (%)	134 (30.9)	47 (24.5)	87 (36.1)	0.1932
H3N2				
Pre-vaccination - GMT (95% CI)	89.3 (77.0 - 103.5)	91.8 (73.0 - 115.4)	87.3 (71.9 - 106.0)	0.8246
Post-vaccination - GMT (95% CI)	363.1 (316.3 - 416.8)	365.0 (292.3 - 455.9)	361.5 (303.5 - 430.6)	0.8793
Pre-vaccination SPR - n (%)	314 (72.5)	141 (73.4)	173 (71.8)	0.8855
Post-vaccination SPR - n (%)	408 (94.2)	179 (93.2)	229 (95.0)	0.4556
Fold-rise (log10) - mean (95% CI)	0.609 (0.559 - 0.660)	0.600 (0.527 - 0.672)	0.617 (0.548 - 0.687)	0.8554
Seroconversion rate - n (%)	207 (47.8)	84 (43.8)	123 (51.0)	0.1807
B				
Pre-vaccination - GMT (95% CI)	262.8 (235.3 - 293.4)	236.3 (204.8 - 272.6)	286.0 (243.1 - 336.4)	0.2847
Post-vaccination - GMT (95% CI)	571.1 (520.2 - 627.1)	508.5 (445.8 - 580.1)	626.5 (549.7 - 714.0)	0.1735
Pre-vaccination SPR - n (%)	424 (97.9)	191 (99.5)	233 (96.7)	0.2887
Post-vaccination SPR - n (%)	433 (100.0)	192 (100.0)	241 (100.0)	0.2887
Fold-rise (log10) - mean (95% CI)	0.337 (0.304 - 0.370)	0.333 (0.288 - 0.378)	0.341 (0.294 - 0.387)	0.9482
Seroconversion rate - n (%)	105 (24.2)	47 (24.5)	58 (24.1)	0.8386

737 * Sex difference p-values derived from multi-level linear (GMT) or logistic regressions (SPR and SCR). Fixed effects included a term for sex and
738 controlled for study year. Random effects included a random intercept on the individual.

739 **Abbreviations & definitions:** CI: confidence interval; Fold-rise: post-vaccination titer divided by pre-vaccination titer, transformed on the log₁₀
740 scale; GMT: geometric mean titer; SPR: seroprotection rate, the proportion of individuals who achieved a titer ≥40; Seroconversion rate: the
741 proportion of individuals who achieved a fold-rise in titer ≥ 4.

742 **Table 3. Sex-specific effects of age on pre-vaccination hemagglutination antibody inhibition (HAI) titers**

	Base Models ^a						Expanded Models ^b					
	Male age effects		Female age effects		Sex difference ^c		Male age effects		Female age effects		Sex difference ^c	
	Change	p-value	Change	p-value	Difference	p-value	Change	p-value	Change	p-value	Difference	p-value
H1N1												
Linear	0.047	0.164	0.034	0.286	-0.014	0.674	0.049	0.152	0.035	0.267	-0.014	0.676
Non-linear												
75-80	0.379	0.300	0.146	0.650	-0.023	0.963	0.383	0.301	0.134	0.685	-0.010	0.984
80-85	0.133	0.564	0.233	0.251	-0.256	0.465	0.131	0.574	0.243	0.238	-0.259	0.462
85-90	0.205	0.397	0.109	0.589	-0.156	0.657	0.220	0.377	0.113	0.593	-0.147	0.678
90-95	0.421	0.188	0.066	0.830	-0.253	0.547	0.430	0.186	0.071	0.817	-0.254	0.553
95					-0.609	0.31					-0.612	0.313
H3N2												
Linear	-0.067	0.133	0.065	0.103	0.131	0.014	-0.075	0.097	0.062	0.121	0.137	0.010
Non-linear												
75-80	-1.725	0.015	-0.156	0.801	-1.898	0.029	-1.776	0.012	-0.297	0.637	-1.833	0.036
80-85	-0.139	0.711	0.653	0.039	-0.328	0.469	-0.102	0.786	0.670	0.037	-0.355	0.435
85-90	0.023	0.953	0.114	0.716	0.463	0.326	-0.048	0.904	0.149	0.651	0.417	0.379
90-95	-0.496	0.39	-0.415	0.430	0.553	0.351	-0.591	0.307	-0.421	0.431	0.614	0.308
95					0.634	0.503					0.784	0.412
B												
Linear	-0.098	0.005	0.009	0.762	0.108	0.007	-0.078	0.023	0.033	0.275	0.111	0.005
Non-linear												
75-80	-0.315	0.516	0.965	0.023	-1.051	0.087	-0.189	0.693	1.203	0.004	-1.048	0.080
80-85	-0.106	0.695	0.161	0.486	0.229	0.511	0.038	0.886	0.219	0.330	0.344	0.298
85-90	-0.291	0.306	-0.534	0.019	0.496	0.165	-0.181	0.515	-0.111	0.633	0.525	0.123
90-95	-1.799	0.000	-0.434	0.248	0.253	0.572	-1.649	0.000	-0.233	0.526	0.595	0.168
95					1.618	0.020					2.011	0.003

743 ^a Base models controlled for study year.744 ^b Expanded models controlled for study year, frailty, and BMI.745 ^c For linear models, the sex-difference is the age-sex interaction term. For non-linear models, the sex difference is at the beginning of each five-year interval.

746 Non-linear models include cubic B-splines with knots at 5-year age intervals from 75-95 years.

747 Statistically significant values are bolded.

748 **Table 4. Goodness-of-fit comparison of pre-vaccination age models**

Age-sex interaction	Base models ^a		Expanded models ^b	
	-	+	-	+
H1N1				
Linear age	1138.86	1140.69	1131.05	1132.87
Non-linear age	1144.47	1151.51	1136.73	1143.72
H3N2				
Linear age	1693.38	1689.57	1666.94	1662.83
Non-linear age	1694.58	1694.83	1667.28	1667.95
B				
Linear age	1398.31	1393.17	1355.04	1349.28
Non-linear age	1388.09	1378.85	1344.94	1337.26

749 ^a Base models controlled for study year.

















750 ^b Expanded models controlled for study year, frailty, and BMI.

751 The lowest AIC, corresponding to the best-fit model, is bolded for each virus.


752

753

Figure 1: Study design

 <ul style="list-style-type: none"> Community-dwelling older adults Age at vaccination: 75+ Study participation: 4+ years 		2014		2015		2016		2017		2018		2019				
		D0	D28	D0	D28	D0	D28	D0	D28	D0	D28	D0	D28			
																
H1N1	A/California/7/2009	█	█	█	█	█	█									
	A/Michigan/45/2015							█	█	█	█					
	A/Brisbane/02/2018											█	█			
H3N2	A/Texas/50/2012	█	█													
	A/Switzerland/9715293/2013			█	█											
	A/Hong Kong/4801/2014					█	█	█	█							
	A/Singapore/INFIMH-16-0019/2016									█	█					
	A/Kansas/14/2017											█	█			
IBV	B/Massachusetts/2/2012 (Yam)	█	█													
	B/Phuket/3073/2013 (Yam)			█	█											
	B/Brisbane/60/2008-like virus (Vic)					█	█	█	█							
	B/Maryland/15/2016 BX-69A (Vic)									█	█	█	█			

 Blood draw

 Frailty & vital signs assessment


 High-dose trivalent inactivated influenza vaccine

Fig 2. Relationship of age, frailty status, and BMI to post-vaccination HAI titers outcomes




Fig 3: Relationship of repeat annual vaccination to post-vaccination HAI titer outcomes




Fig 4. Relationship between pre-vaccination HAI titers and post-vaccination HAI titer outcomes




Fig 5. Relationship of age, frailty status, and BMI to pre-vaccination HAI titers

